---
document_datetime: 2025-12-02 05:24:47
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/trizivir.html
document_name: trizivir.html
version: success
processing_time: 0.1008433
conversion_datetime: 2025-12-28 02:46:26.635523
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Trizivir

[RSS](/en/individual-human-medicine.xml/65800)

##### Authorised

This medicine is authorised for use in the European Union

abacavir / lamivudine / zidovudine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Trizivir](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Trizivir is used to treat adults who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS). It is used to replace treatment with the three active substances (abacavir, lamivudine and zidovudine) taken separately at doses similar to those in Trizivir. Patients should have been taking the three active substances separately for at least 6 weeks before switching to Trizivir.

Trizivir contains three active substances: abacavir, lamivudine and zidovudine.

Expand section

Collapse section

## How is Trizivir used?

Trizivir can only be obtained with a prescription and treatment should be started by a doctor who has experience in managing HIV infection.

Before starting treatment with abacavir, all patients should have a test to find out if they have a gene called 'HLA?B (type 5701)'. Patients with this gene are at an increased risk of having an allergic reaction to abacavir, so they should not take Trizivir.

Trizivir is available as tablets (300 mg abacavir/150 mg lamivudine/300 mg zidovudine). The recommended dose is one tablet twice a day. If patients need to stop taking abacavir, lamivudine or zidovudine, or need to take different doses because of problems with their kidneys, liver or blood, they will need to take medicines containing abacavir, lamivudine or zidovudine separately. For more information about using Trizivir, see the package leaflet or contact your doctor or pharmacist.

## How does Trizivir work?

All three active substances in Trizivir, abacavir, lamivudine, and zidovudine, are nucleoside reverse transcriptase inhibitors (NRTIs). They work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to make more copies of itself in the cells it has infected and so spread in the body. Trizivir does not cure HIV infection but it reduces the amount of HIV in the blood and keeps it at a low level. This holds off damage to the immune system and the development of infections and diseases associated with AIDS.

All three active substances have been available in the European Union (EU) for a number of years: abacavir has been authorised as Ziagen since 1999, lamivudine has been authorised as Epivir since 1996, and zidovudine has been available in the EU since the mid?1980s.

## What benefits of Trizivir have been shown in studies?

No specific clinical studies have been carried out to assess the safety and effectiveness of the combined tablet. The company presented the results of studies with abacavir, lamivudine and zidovudine taken together, which were carried out during the development of Ziagen. In these studies, the combination of the three active substances was shown to be at least as effective as the comparator combinations in keeping viral loads low.

The company also looked at the way the combined tablet was absorbed in the body in comparison with the separate tablets. The combination tablet was absorbed in the body in the same way as the separate tablets.

## What are the risks associated with Trizivir?

The most common effects with Trizivir (which may affect more than 1 in 10 people) are headache and nausea (feeling sick). For the full list of side effects of Trizivir, see the package leaflet.

Hypersensitivity reactions (allergic reactions) occur in patients taking Trizivir, usually within the first 6 weeks of treatment, and can be life-threatening. The risk of hypersensitivity is higher in patients who have the HLA?B (type 5701) gene. Symptoms almost always include fever or rash, but also very commonly include nausea, vomiting, diarrhoea, abdominal (belly) pain, headache, blood tests showing signs of liver damage, muscle pain, dyspnoea (difficulty breathing), cough, lethargy (lack of energy) and feeling unwell. Treatment with Trizivir should be stopped promptly if the patient has a hypersensitivity reaction. For more information, see the package leaflet.

Trizivir must not be used in patients who have kidney failure. Because it contains zidovudine, Trizivir must not be used by patients with low neutrophil counts (low levels of a type of white blood cell) or anaemia (low red blood cell counts). For the full list of restrictions, see the package leaflet.

## Why is Trizivir authorised in the EU?

The European Medicines Agency noted that reducing the number of tablets that patients need to take may help patients stick to their treatment. The Agency therefore decided that Trizivir's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Trizivir?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Trizivir have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Trizivir are continuously monitored. Side effects reported with Trizivir are carefully evaluated and any necessary action taken to protect patients.

## Other information about Trizivir

Trizivir received a marketing authorisation valid throughout the EU on 28 December 2000.

Trizivir : EPAR - Summary for the public

Reference Number: EMA/197378/2020

English (EN) (128.75 KB - PDF)

**First published:** 29/01/2008

**Last updated:** 28/07/2020

[View](/en/documents/overview/trizivir-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-129)

български (BG) (154.04 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/bg/documents/overview/trizivir-epar-summary-public_bg.pdf)

español (ES) (128.74 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/es/documents/overview/trizivir-epar-summary-public_es.pdf)

čeština (CS) (150.2 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/cs/documents/overview/trizivir-epar-summary-public_cs.pdf)

dansk (DA) (127.43 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/da/documents/overview/trizivir-epar-summary-public_da.pdf)

Deutsch (DE) (130.91 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/de/documents/overview/trizivir-epar-summary-public_de.pdf)

eesti keel (ET) (134.54 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/et/documents/overview/trizivir-epar-summary-public_et.pdf)

ελληνικά (EL) (153.63 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/el/documents/overview/trizivir-epar-summary-public_el.pdf)

français (FR) (129.75 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/fr/documents/overview/trizivir-epar-summary-public_fr.pdf)

hrvatski (HR) (149.11 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/hr/documents/overview/trizivir-epar-summary-public_hr.pdf)

italiano (IT) (82.46 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/it/documents/overview/trizivir-epar-summary-public_it.pdf)

latviešu valoda (LV) (166.05 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/lv/documents/overview/trizivir-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (150.26 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/lt/documents/overview/trizivir-epar-summary-public_lt.pdf)

magyar (HU) (149.09 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/hu/documents/overview/trizivir-epar-summary-public_hu.pdf)

Malti (MT) (160.87 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/mt/documents/overview/trizivir-epar-summary-public_mt.pdf)

Nederlands (NL) (128.04 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/nl/documents/overview/trizivir-epar-summary-public_nl.pdf)

polski (PL) (153.21 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/pl/documents/overview/trizivir-epar-summary-public_pl.pdf)

português (PT) (129.55 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/pt/documents/overview/trizivir-epar-summary-public_pt.pdf)

română (RO) (155.44 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/ro/documents/overview/trizivir-epar-summary-public_ro.pdf)

slovenčina (SK) (152.01 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/sk/documents/overview/trizivir-epar-summary-public_sk.pdf)

slovenščina (SL) (147.33 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/sl/documents/overview/trizivir-epar-summary-public_sl.pdf)

Suomi (FI) (126.89 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/fi/documents/overview/trizivir-epar-summary-public_fi.pdf)

svenska (SV) (127.58 KB - PDF)

**First published:**

29/01/2008

**Last updated:**

28/07/2020

[View](/sv/documents/overview/trizivir-epar-summary-public_sv.pdf)

## Product information

Trizivir : EPAR - Product Information

English (EN) (579.85 KB - PDF)

**First published:** 09/12/2009

**Last updated:** 29/11/2022

[View](/en/documents/product-information/trizivir-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-83)

български (BG) (891.85 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/bg/documents/product-information/trizivir-epar-product-information_bg.pdf)

español (ES) (642.6 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/es/documents/product-information/trizivir-epar-product-information_es.pdf)

čeština (CS) (751.81 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/cs/documents/product-information/trizivir-epar-product-information_cs.pdf)

dansk (DA) (650.42 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/da/documents/product-information/trizivir-epar-product-information_da.pdf)

Deutsch (DE) (658.79 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/de/documents/product-information/trizivir-epar-product-information_de.pdf)

eesti keel (ET) (692.33 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/et/documents/product-information/trizivir-epar-product-information_et.pdf)

ελληνικά (EL) (723.33 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/el/documents/product-information/trizivir-epar-product-information_el.pdf)

français (FR) (678 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/fr/documents/product-information/trizivir-epar-product-information_fr.pdf)

hrvatski (HR) (694.95 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/hr/documents/product-information/trizivir-epar-product-information_hr.pdf)

íslenska (IS) (628.97 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/is/documents/product-information/trizivir-epar-product-information_is.pdf)

italiano (IT) (648.08 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/it/documents/product-information/trizivir-epar-product-information_it.pdf)

latviešu valoda (LV) (751.48 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/lv/documents/product-information/trizivir-epar-product-information_lv.pdf)

lietuvių kalba (LT) (675.96 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/lt/documents/product-information/trizivir-epar-product-information_lt.pdf)

magyar (HU) (742.42 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/hu/documents/product-information/trizivir-epar-product-information_hu.pdf)

Malti (MT) (830.22 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/mt/documents/product-information/trizivir-epar-product-information_mt.pdf)

Nederlands (NL) (624.3 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/nl/documents/product-information/trizivir-epar-product-information_nl.pdf)

norsk (NO) (605.18 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/no/documents/product-information/trizivir-epar-product-information_no.pdf)

polski (PL) (744.95 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/pl/documents/product-information/trizivir-epar-product-information_pl.pdf)

português (PT) (599.64 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/pt/documents/product-information/trizivir-epar-product-information_pt.pdf)

română (RO) (712.87 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/ro/documents/product-information/trizivir-epar-product-information_ro.pdf)

slovenčina (SK) (714.68 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/sk/documents/product-information/trizivir-epar-product-information_sk.pdf)

slovenščina (SL) (654.57 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/sl/documents/product-information/trizivir-epar-product-information_sl.pdf)

Suomi (FI) (607.75 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/fi/documents/product-information/trizivir-epar-product-information_fi.pdf)

svenska (SV) (605.84 KB - PDF)

**First published:**

09/12/2009

**Last updated:**

29/11/2022

[View](/sv/documents/product-information/trizivir-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00003144/202212 15/11/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Trizivir : EPAR - All Authorised presentations

English (EN) (21.77 KB - PDF)

**First published:** 07/08/2006

**Last updated:** 27/09/2022

[View](/en/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-11)

български (BG) (37.05 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/bg/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_bg.pdf)

español (ES) (19.97 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/es/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_es.pdf)

čeština (CS) (78.8 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/cs/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (37.95 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/da/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (16.65 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/de/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (7.15 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/et/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (442.41 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/el/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_el.pdf)

français (FR) (12.81 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/fr/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (39.49 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/hr/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (8.61 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/is/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_is.pdf)

italiano (IT) (32.94 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/it/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (38.76 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/lv/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (68.1 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/lt/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (38.95 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/hu/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (28.05 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/mt/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (41.87 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/nl/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (12.4 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/no/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_no.pdf)

polski (PL) (58.41 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/pl/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_pl.pdf)

português (PT) (24.69 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/pt/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_pt.pdf)

română (RO) (58.68 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/ro/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (49.66 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/sk/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (21.66 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/sl/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (41.16 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/fi/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (33.48 KB - PDF)

**First published:**

07/08/2006

**Last updated:**

27/09/2022

[View](/sv/documents/all-authorised-presentations/trizivir-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Trizivir Active substance

- abacavir (as sulfate)
- lamivudine
- zidovudine

International non-proprietary name (INN) or common name

- abacavir
- lamivudine
- zidovudine

Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AR04

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Trizivir is indicated for the treatment of human-immunodeficiency-virus (HIV) infection in adults.

This fixed combination replaces the three components (abacavir, lamivudine and zidovudine) used separately in similar dosages. It is recommended that treatment is started with abacavir, lamivudine,and zidovudine separately for the first six to eight weeks. The choice of this fixed combination should be based not only on potential adherence criteria, but mainly on expected efficacy and risk related to the three nucleoside analogues.

The demonstration of the benefit of Trizivir is mainly based on results of studies performed in treatment naive patients or moderately antiretroviral experienced patients with non-advanced disease.

In patients with high viral load (&gt;100,000 copies/ml) choice of therapy needs special consideration.

Overall, the virologic suppression with this triple nucleoside regimen could be inferior to that obtained with other multitherapies notably including boosted protease inhibitors or non-nucleoside reverse-transcriptase inhibitors, therefore the use of Trizivir should only be considered under special circumstances (e.g. co-infection with tuberculosis).

Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Screening is also recommended prior to re-initiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir (see 'management after an interruption of Trizivir therapy'). Abacavir should not be used in patients known to carry the HLA-B*5701 allele, unless no other therapeutic option is available in these patients, based on the treatment history and resistance testing.

## Authorisation details

EMA product number EMEA/H/C/000338 Marketing authorisation holder

ViiV Healthcare BV

Van Asch van Wijckstraat 55H

Opinion adopted 21/09/2000 Marketing authorisation issued 27/12/2000 Revision 43

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Trizivir : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (532.24 KB - PDF)

**First published:** 09/12/2009

**Last updated:** 29/11/2023

[View](/en/documents/procedural-steps-after/trizivir-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Trizivir-H-C-PSUSA-00003144-202212 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/395778/2023

English (EN) (103.35 KB - PDF)

**First published:** 29/11/2023

[View](/en/documents/scientific-conclusion/trizivir-h-c-psusa-00003144-202212-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Trizivir : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (90.64 KB - PDF)

**First published:** 07/08/2006

**Last updated:** 07/08/2006

[View](/en/documents/steps-after-cutoff/trizivir-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Trizivir : EPAR - Scientific Discussion

English (EN) (247.16 KB - PDF)

**First published:** 07/08/2006

**Last updated:** 07/08/2006

[View](/en/documents/scientific-discussion/trizivir-epar-scientific-discussion_en.pdf)

Trizivir : EPAR - Procedural steps taken before authorisation

English (EN) (89.16 KB - PDF)

**First published:** 07/08/2006

**Last updated:** 07/08/2006

[View](/en/documents/procedural-steps/trizivir-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Trizivir

[Updated advice on body fat changes and lactic acidosis with HIV medicines](/en/news/updated-advice-body-fat-changes-lactic-acidosis-hiv-medicines) 23/10/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 October 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-october-2015) 23/10/2015

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 29/11/2023

## Share this page

[Back to top](#main-content)